SEARCH

SEARCH BY CITATION

References

  • Altman, R., Scazziota, A., De Lourdes Herrera, M. & Gonzalez, C. (2006) Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. Journal of Thrombosis & Haemostasis, 4, 20222027.
  • Ammar, T. & Fisher, C.F. (1997) The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology, 86, 13821386.
  • Bang, C.J., Berstad, A. & Talstad, I. (1991) Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis, 21, 155160.
  • Benedict, C.R., Refino, C.J., Keyt, B.A., Pakala, R., Paoni, N.F., Thomas, G.R. & Bennett, W.F. (1995) New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation, 92, 30323040.
  • Berkowitz, S.D., Harrington, R.A., Rund, M.M. & Tcheng, J.E. (1997) Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation, 95, 809813.
  • Bhala, N., Taggar, J.S., Rajasekhar, P. & Banerjee, A. (2011) Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment. British Medical Journal, 343, d4264.
  • Bijsterveld, N.R., Moons, A.H., Boekholdt, S.M., van Aken, B.E., Fennema, H., Peters, R.J.G., Meijers, J.C.M., Buller, H.R. & Levi, M. (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation, 106, 25502554.
  • Blomback, M., He, S., Bark, N., Wallen, H.N. & Elg, M. (2011) Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. British Journal of Haematology, 152, 758765.
  • Boersma, E., Harrington, R.A., Moliterno, D.J., White, H., Theroux, P., Van de Werf, F., de Torbal, A., Armstrong, P.W., Wallentin, L.C., Wilcox, R.G., Simes, J., Califf, R.M., Topol, E.J. & Simoons, M.L. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 359, 189198.
  • Broderick, J., Connolly, S., Feldmann, E., Hanley, D., Kase, C., Krieger, D., Mayberg, M., Morgenstern, L., Ogilvy, C.S., Vespa, P. & Zuccarello, M., American Heart, Association, American Stroke Association Stroke, Council, High Blood Pressure Research, Council, Quality of, Care & Outcomes in Research Interdisciplinary Working, Group (2007) Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke, 38, 20012023.
  • Burger, W., Chemnitius, J.M., Kneissl, G.D., Rucker, G., Burger, W., Chemnitius, J.M., Kneissl, G.D. & Rucker, G. (2005) Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. Journal of Internal Medicine, 257, 399414.
  • Chan, S., Kong, M., Minning, D.M., Hedner, U. & Marder, V.J. (2003) Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. Journal of Thrombosis and Haemostasis, 1, 760765.
  • Chew, D.P. (2002) Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures. Hamostaseologie, 22, 6066.
  • Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D. & Wallentin, L. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 11391151.
  • Crowther, M.A. & Warkentin, T.E. (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood, 111, 48714879.
  • Crowther, M.A. & Warkentin, T.E. (2009) Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. Journal of Thrombosis and Haemostasis, 7, 107110.
  • Danhof, M., de, B.A., Magnani, H.N. & Stiekema, J.C. (1992) Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis, 22, 7384.
  • Dao, A., Tuan, B. & Carlson, N. (2005) Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa. American Journal of Medicine, 118, 11721173.
  • Desmurs-Clavel, H., Huchon, C., Chatard, B., Negrier, C. & Dargaud, Y. (2009) Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thrombosis Research, 123, 796798.
  • Donat, F., Duret, J.P., Santoni, A., Cariou, R., Necciari, J., Magnani, H. & de, G.R. (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clinical Pharmacokinetics, 41, 19.
  • Edwards, J.T., Hamby, J.K. & Worrall, N.K. (2003) Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. The Annals of Thoracic Surgery, 75, 16221624.
  • Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R. & Levi, M. (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124, 15731579.
  • Eikelboom, J.W., Mehta, S.R., Anand, S.S., Xie, C., Fox, K.A. & Yusuf, S. (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation, 114, 774782.
  • Elg, M., Carlsson, S. & Gustafsson, D. (2001) Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thrombosis Research, 101, 145157.
  • Fernandes, P., Mayer, R., MacDonald, J.L., Cleland, A.G. & Hay-McKay, C. (2000) Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases. Perfusion, 15, 531539.
  • Gasparovic, H., Nathan, N.S., Fitzgerald, D. & Aranki, S.F. (2004) Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. The Annals of Thoracic Surgery, 78, e89– e91.
  • Gatt, A., van Veen, J.J., Woolley, A.M., Kitchen, S., Cooper, P. & Makris, M. (2008) Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thrombosis and Haemostasis, 100, 350355.
  • Genzen, J.R., Fareed, J., Hoppensteadt, D., Kurup, V., Barash, P., Coady, M. & Wu, Y.Y. (2010) Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Transfusion, 50, 801807.
  • Giorgi, M.A., Cohen Arazi, H., Gonzalez, C.D. & Di Girolamo, G. (2011) Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opinion on Pharmacotherapy, 12, 12851295.
  • Gitlin, S.D., Deeb, G.M., Yann, C. & Schmaier, A.H. (1998) Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. Journal of Vascular Surgery, 27, 568575.
  • Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A.M., Emmerich, J., Marchand-Leroux, C., Lecompte, T. & Samama, C.M. (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology, 116, 94102.
  • Goldstein, J.N., Marrero, M., Masrur, S., Pervez, M., Barrocas, A.M., Abdullah, A., Oleinik, A., Rosand, J., Smith, E.E., Dzik, W.H. & Schwamm, L.H. (2010) Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Archives of Neurology, 67, 965969.
  • Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al (2011) Apixaban versus warfarin in patients with atrial fibrillarion. New England Journal of Medicine, 365, 981992.
  • Gray, E., Mulloy, B. & Barrowcliffe, T.W. (2008) Heparin and low-molecular-weight heparin. Thrombosis and Haemostasis, 99, 807818.
  • Gruber, A., Marzec, U.M., Buetehorn, U.M., Hanson, S. & Perzborn, E. (2008) Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood, Vol. 112, p. Poster 3825.
  • Gurbel, P.A., Hayes, K., Bliden, K.P., Yoho, J. & Tantry, U.S. (2005) The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagulation & Fibrinolysis, 16, 17.
  • Hirsh, J. (1992) Orgaran. Extending the frontiers of venous thrombosis prophylaxis. Summary and conclusions, Pathophysiology of Haemostasis and Thrombosis, Vol. 22, 112.
  • Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M. & Weitz, J.I. (2008) Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 141S159S.
  • Hoffmeister, H.M., Kastner, C., Szabo, S., Beyer, M.E., Helber, U., Kazmaier, S., Baumbach, A., Wendel, H.P. & Heller, W. (2000) Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction. American Journal of Cardiology, 86, 263268.
  • Holst, J., Lindblad, B., Bergqvist, D., Garre, K., Nielsen, H., Hedner, U. & Ostergaard, P.B. (1994) Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagulation & Fibrinolysis, 5, 795803.
  • Horlocker, T.T., Wedel, D.J., Benzon, H., Brown, D.L., Enneking, F.K., Heit, J.A., Mulroy, M.F., Rosenquist, R.W., Rowlingson, J., Tryba, M., Yuan, C.S., Horlocker, T.T., Wedel, D.J., Benzon, H., Brown, D.L., Enneking, F.K., Heit, J.A., Mulroy, M.F., Rosenquist, R.W., Rowlingson, J., Tryba, M. & Yuan, C.-S. (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Regional Anesthesia & Pain Medicine, 28, 172197.
  • Howard-Alpe, G.M., de Bono, J., Hudsmith, L., Orr, W.P., Foex, P., Sear, J.W., Howard-Alpe, G.M., de Bono, J., Hudsmith, L., Orr, W.P., Foex, P. & Sear, J.W. (2007) Coronary artery stents and non-cardiac surgery. British Journal of Anaesthesia, 98, 560574.
  • Huvers, F., Slappendel, R., Benraad, B., Van Hellemondt, G. & Van Kraaij, M. (2005) Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Netherlands.Journal.of Medicine, 63, 184186.
  • Ingerslev, J., Vanek, T. & Culic, S. (2007) Use of recombinant factor VIIa for emergency reversal of anticoagulation. Journal of Postgraduate Medicine, 53, 1722.
  • Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S. & Makris, M. (2011) Guidelines on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology, 154, 311324.
  • Korte, W., Cattaneo, M., Chassot, P.G., Eichinger, S., von Heymann, C., Hofmann, N., Rickli, H., Spannagl, M., Ziegler, B., Verheugt, F. & Huber, K. (2011) Peri-operative management of antiplatelet therapy in patients with coronary artery disease. Thrombosis and Haemostasis, 105, 743749.
  • Koster, A., Buz, S., Krabatsch, T., Dehmel, F., Kuppe, H., Hetzer, R., Aronson, S. & Dyke, C.M. (2008) Effect of modified ultrafiltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different filtration strategies. Journal of Cardiac Surgery, 23, 655658.
  • Lauritzen, B., Hedner, U., Johansen, P.B., Tranholm, M. & Ezban, M. (2008) Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. Journal of Thrombosis and Haemostasis, 6, 804811.
  • Leithauser, B., Zielske, D., Seyfert, U.T., Jung, F., Leithauser, B., Zielske, D., Seyfert, U.T. & Jung, F. (2008) Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clinical Hemorheology and Microcirculation, 39, 293302.
  • Levi, M., Levy, J.H., Andersen, H.F. & Truloff, D. (2010) Safety of recombinant activated factor VII in randomized clinical trials. New England Journal of Medicine, 363, 17911800.
  • Levi, M., Eerenberg, E. & Kamphuisen, P.W. (2011) Bleeding risk and reversal strategies for old and new anticoagulants and anti-platelet agents. Journal of Thrombosis and Haemostasis, 9, 17061712.
  • Li, C., Hirsh, J., Xie, C., Johnston, M.A. & Eikelboom, J.W. (2012) Reversal of the anti-platelet effects of aspirin and clopidogrel. Journal of Thrombosis and Haemostasis, 10, 521528.
  • Lindblad, B., Borgstrom, A., Wakefield, T.W., Whitehouse, W.M. Jr & Stanley, J.C. (1987) Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thrombosis Research, 48, 3140.
  • Linkins, L.A., Choi, P.T. & Douketis, J.D. (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Annals of Internal Medicine, 139, 893900.
  • Luporsi, P., Chopard, R., Janin, S., Racadot, E., Bernard, Y., Ecarnot, F., Seronde, M.F., Briand, F., Guignier, A., scotes-Genon, V., Meneveau, N. & Schiele, F. (2011) Use of recombinant factor VIIa (NovoSeven©) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Cardiac Care, 13, 9398.
  • Madan, M. & Berkowitz, S.D. (1999) Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. American Heart Journal, 138, 317326.
  • Magnani, H.N. & Gallus, A. (2006) Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thrombosis and Haemostasis, 95, 967981.
  • Malherbe, S., Tsui, B.C.H., Stobart, K. & Koller, J. (2004) Argatroban as anticoagulant in cardiopulmonary bypass in an Infant and attempted reversal with recombinant activated factor VII. Anesthesiology, 100, 443445.
  • Mannucci, P.M. & Levi, M. (2007) Prevention and treatment of major blood loss. The Netherlands Journal of Medicine, 356, 23012311.
  • Mannucci, P.M., Vicente, V., Vianello, L., Cattaneo, M., Alberca, I., Coccato, M.P., Faioni, E., Mari, D., Mannucci, P.M., Vicente, V., Vianello, L., Cattaneo, M., Alberca, I., Coccato, M.P., Faioni, E. & Mari, D. (1986) Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood, 67, 11481153.
  • Melandri, G., Vagnarelli, F., Calabrese, D., Semprini, F., Nanni, S. & Branzi, A. (2009) Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vascular Health and Risk Management, 5, 249256.
  • Moser, M., Nordt, T., Peter, K., Ruef, J., Kohler, B., Schmittner, M., Smalling, R., Kubler, W. & Bode, C. (1999) Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. Circulation, 100, 18581864.
  • Nawarskas, J.J. & Snowden, S.S. (2011) Critical appraisal of ticagrelor in the management of acute coronary syndrome. Therapeutics and Clinical Risk Management, 7, 473488.
  • Ni Ainle, F., Preston, R.J., Jenkins, P.V., Nel, H.J., Johnson, J.A., Smith, O.P., White, B., Fallon, P.G. & O'Donnell, J.S. (2009) Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood, 114, 16581665.
  • Olesen, J.B., Christiansen, K., Ingerslev, J., Sorensen, B. & Hvas, A. (2009) Haemostatic response to in vitro addition of recombinant factor Vila, prothrombin complex concentrate, or concentrate of Factor IX/X in blood spiked with a direct Xa inhibitor. Journal of Thrombosis and Haemostasis, 7 (Suppl. 2), PP-Mo-386.
  • Pamboukian, S.V., Ignaszewski, A.P. & Ross, H.J. (2000) Management strategies for heparin-induced thrombocytopenia in heart-transplant candidates: case report and review of the literature. Journal of Heart and Lung Transplantation, 19, 810814.
  • Patel, M.R., Mahaffey, K.W. & Garg, J. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365, 883891.
  • Peerlinck, K., De Lepeleire, I., Goldberg, M., Farrell, D., Barrett, J., Hand, E., Panebianco, D., Deckmyn, H., Vermylen, J. & Arnout, J. (1993) MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation, 88, 15121517.
  • Perzborn, E. & Harwardt, M. (2007) Recombinant factor VIIa partially reverses the effects of the factor anti Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. Journal of Thrombosis and Haemostasis, Vol. 5 (Suppl. 2), pp. P-W-640.
  • Porsche, R. & Brenner, Z.R. (1999) Allergy to protamine sulfate. Heart & Lung: The Journal of Critical Care, 28, 418428.
  • Price, M.J., Logan, D.K., Walder, J.S., Baker, B.A., Heiselman, D.E., Jakubowski, J.A., Winters, K.J., Li, W. & Angiolillo, D.J. (2011) Recovery of platelet function following discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated subjects with stable coronary artery disease: The RECOVERY Trial. Journal of the American College of Cardiology, 57, E1636.
  • Van Ryn, J., Ruehl, D., Priepke, H., Hauel, N. & Wienen, W. (2008) Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran by recombinant factor VIIa or activated prothrombin concentrate complex. Haematologica, 93, 148.
  • van Ryn, J., Sieger, P., Kink-Eiband, M., Gansser, D. & Clemens, A. (2009) Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood, (ASH Annual Meeting Abstracts) 114, 1065.
  • Van Ryn, J., Drr, B., Kaspereit, F., Krege, W., Zeitler, S. & Pragst, I. (2010a) Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits. Pathophysiology of Haemostasis and Thrombosis, 37, A94.
  • Van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K.H., Wienen, W., Feuring, M. & Clemens, A. (2010b) Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis, 103, 11161127.
  • Van Ryn, J., Neubauer, M., Flieg, R., Krause, B., Storr, M., Hauel, N., Priepke, H. & Clemens, A. (2010c) Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haematologica, 95, 293.
  • Van Ryn-McKenna, J., Cai, L., Ofosu, F.A., Hirsh, J. & Buchanan, M.R. (1990) Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thrombosis and Haemostasis, 63, 271274.
  • Samama, M.M. & Gerotziafas, G.T. (2003) Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thrombosis Research, 109, 111.
  • Schmahl, K.S., Ganjoo, A.K. & Harloff, M.G. (1997) Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: Role of adjunctive plasmapheresis. Journal of Cardiothoracic and Vascular Anesthesia, 11, 262263.
  • Serebruany, V.L., Malinin, A.I., Callahan, K.P., Binbrek, A., Van De Werf, F., Alexander, J.H., Granger, C.B. & Gurbel, P.A., Assessment of the, Safety & Efficacy of a New Thrombolytic Agent platelet, substudy (2003) Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. American Heart Journal, 145, 636642.
  • Simpson, D., Siddiqui, M.A.A., Scott, L.J. & Hilleman, D.E. (2006) Reteplase: a review of its use in the management of thrombotic occlusive disorders. American Journal of Cardiovascular Drugs, 6, 265285.
  • Smith, B.S. & Gandhi, P.J. (2001) Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. Journal of Thrombosis and Thrombolysis, 11, 3948.
  • Sorour, Y., Van Veen, J.J. & Makris, M. (2010) Recombinant factor VIIa for unlicensed indications – a definite No or a cautious Maybe in selected patients. International Journal of Clinical Practice, 64, 14681471.
  • Stangier, J., Rathgen, K., Stahle, H. & Mazur, D. (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clinical Pharmacokinetics, 49, 259268.
  • Stangl, K., Laule, M., Tenckhoff, B., Stangl, V., Gliech, V., Dubel, P., Grohmann, A., Melzer, C., Langel, J., Wernecke, K.D., Baumann, G. & Ziemer, S. (1998) Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction. American Journal of Cardiology, 81, 841847.
  • Stewart, D., Kong, M., Novokhatny, V., Jesmok, G. & Marder, V.J. (2003) Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood, 101, 30023007.
  • Szabo, S., Letsch, R., Ehlers, R., Walter, T., Kazmaier, S., Helber, U. & Hoffmeister, H.M. (2002) Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. Thrombosis Research, 106, 113119.
  • Tanne, D., Macko, R.F., Lin, Y., Tilley, B.C. & Levine, S.R. & NINDS rtPA Stroke Study Group. (2006) Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke, 37, 17981804.
  • Tcheng, J.E., Ellis, S.G., George, B.S., Kereiakes, D.J., Kleiman, N.S., Talley, J.D., Wang, A.L., Weisman, H.F., Califf, R.M. & Topol, E.J. (1994) Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation, 90, 17571764.
  • Tcheng, J.E., Kereiakes, D.J., Lincoff, A.M., George, B.S., Kleiman, N.S., Sane, D.C., Cines, D.B., Jordan, R.E., Mascelli, M.A., Langrall, M.A., Damaraju, L., Schantz, A., Effron, M.B. & Braden, G.A. (2001) Abciximab readministration: results of the ReoPro Readministration Registry. Circulation, 104, 870875.
  • Tracy, R.P., Rubin, D.Z., Mann, K.G., Bovill, E.G., Rand, M., Geffken, D. & Tracy, P.B. (1997) Thrombolytic therapy and proteolysis of factor V. Journal of the American College of Cardiology, 30, 716724.
  • Uchino, K., Pary, J. & Grotta, J. (2011) Acute Stroke Care. A Manual from the University of Texas-Houston Stroke Team. Cambridge University Press, Cambridge, UK. ISBN 978-0-521-18484-7.
  • Van Veen, J.J., Maclean, R.M., Hampton, K.K., Laidlaw, S., Kitchen, S., Toth, P. & Makris, M. (2011) Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagulation & Fibrinolysis, 22, 565570.
  • Vilahur, G., Choi, B.G., Zafar, M.U., Viles-Gonzalez, J.F., Vorchheimer, D.A., Fuster, V., Badimon, J.J., Vilahur, G., Choi, B.G., Zafar, M.U., Viles-Gonzalez, J.F., Vorchheimer, D.A., Fuster, V. & Badimon, J.J. (2007) Normalization of platelet reactivity in clopidogrel-treated subjects. Journal of Thrombosis & Haemostasis, 5, 8290.
  • Warkentin, T.E., Greinacher, A. & Koster, A. (2008) Bivalirudin. Thrombosis and Haemostasis, 99, 830839.
  • Warkentin, T.E., Margetts, P., Connolly, S.J., Lamy, A., Ricci, C. & Eikelboom, J.W. (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood, 119, 21722174.
  • Weber, A.A., Braun, M., Hohlfeld, T., Schwippert, B., Tschope, D., Schror, K., Weber, A.A., Braun, M., Hohlfeld, T., Schwippert, B., Tschope, D. & Schror, K. (2001) Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. British Journal of Clinical Pharmacology, 52, 333336.
  • Wechsler, L.R. (2011) Intravenous thrombolytic therapy for acute ischemic stroke. New England Journal of Medicine, 364, 21382146.
  • Van de Werf, F. (1999) What do new lytics add to t-PA? American Heart Journal, 138, S115120.
  • Westphal, K., Martens, S., Strouhal, U., Matheis, G., Lindhoff-Last, E., Wimmer-Greinecker, G. & Lischke, V. (1997) Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure. The Thoracic and Cardiovascular Surgeon, 45, 318320.
  • Wolzt, M., Levi, M., Sarich, T.C., Bostrom, S.L., Erikkson, U.G., Erikkson-Lepkowska, M., Svensson, M., Weitz, J.I., Elg, M. & Wahlander, K. (2004) Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and Haemostasis, 91, 10901096.
  • Young, G., Yonekawa, K.E., Nakagawa, P.A., Blain, R.C., Lovejoy, A.E. & Nugent, D.J. (2007) Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagulation & Fibrinolysis, 18, 547553.